Tender

TENDER FOR THE DEVELOPMENT AND SUPPLY OF A SALIVA-BASED LATERAL FLOW IMMUNOASSAY

THE UNIVERSITY OF BIRMINGHAM

This public procurement record has 1 release in its history.

Tender

27 Mar 2024 at 13:44

Summary of the contracting process

The University of Birmingham is seeking tenders for the development and supply of a saliva-based lateral flow immunoassay to detect antibodies in human saliva samples. The key target specifications include high sensitivity detection, quick performance, reader-free operation, and suitability for field settings. The total value of this tender is £230,000. The procurement method is an open procedure. The tender period ends on 26th April 2024, with the award period starting immediately after. The University of Birmingham is the buying organisation for this tender.

This tender provides opportunities for businesses involved in laboratory, optical, and precision equipment to compete. Companies certified to ISO 13485 and able to develop tests compliant with IVDR 2017/746 requirements are well-suited for this opportunity. Businesses with expertise in developing low-cost, environmentally friendly medical devices suitable for community settings will find this tender relevant. The University of Birmingham aims to support future manufacture, scale-up, and distribution of the developed test, offering long-term growth potential for successful bidders.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

TENDER FOR THE DEVELOPMENT AND SUPPLY OF A SALIVA-BASED LATERAL FLOW IMMUNOASSAY

Notice Description

The University of Birmingham invites tenders for the development and supply of lateral flow immunoassay. The lateral flow is intended to be used to detect antibodies in human saliva samples. Specifically, the lateral flow assay needs to be able to detect IgG-class anti-tetanus antibodies. The lateral flow immunoassay will need to be developed to meet the following key target specifications: High sensitivity detection that can differentiate protective antibody status. To enable its use with saliva specimens, the test will need to have a low limit of detection. The test positivity threshold needs to be equivalent to the WHO protective threshold of 0.1 IU/mL in serum. Proof of concept studies at the University of Birmingham estimate that the protective cut-off in serum is equivalent to ~ 0.0024 IU/mL in saliva. Minimal time to perform, able to be completed with a small number of simple steps and return a result within 15 minutes. Reader-free and return a qualitative (positive or negative) result. The method of saliva sample collection to accompany the test needs to be suitable for use in young children and infants. The test should be able to be completed by a non-specialist and in a community or field setting. The test should have no linked required cold chain, able to withstand hot/humid temperatures on land and able to withstand conditions associated with transport by both aeroplane and drone. The test needs to be stable, with a long-term stability time equivalent to existing commercial lateral flow tests. The design of the test needs to be as low-cost as possible. This is to enable its use in low-middle income countries or low resource settings. The test design also needs to strongly reflect environmental considerations. Specifically, an unhoused test strip is desirable. The sample collection and application, and any other test components, should be designed and utilised with the objective of using as little plastic as possible and minimal packaging. The project will require developing the test to meet these desired specifications, evaluating the test performance (for example performance around the cut-off, reproducibility, stability and any other relevant domains, as informed by international guidelines on test evaluation e.g. CLSI) and supplying UoB with devices. Small batches of devices (~ 200) will need to be supplied to UoB at various points in the development to assess clinical accuracy. On completion of the project, the CRO will need to be able to supply UoB with up to 1000 devices suitable for use at the point of care as part of an in-field evaluation study. The development needs to be carried out within appropriate Quality Management Systems and in accordance with regulatory requirements for medical devices. The supplier should be certified to ISO 13485 and able to develop test to be compliant with IVDR 2017/746 requirements. The project should include the compiling and supply of relevant documentation and files to support future submission for regulatory approval. Post-project, the CRO should be able to support any future manufacture, scale-up and distribution of the test.

Lot Information

Lot 1

The University of Birmingham invites tenders for the development and supply of lateral flow immunoassay. The lateral flow is intended to be used to detect antibodies in human saliva samples. Specifically, the lateral flow assay needs to be able to detect IgG-class anti-tetanus antibodies. The lateral flow immunoassay will need to be developed to meet the following key target specifications: High sensitivity detection that can differentiate protective antibody status. To enable its use with saliva specimens, the test will need to have a low limit of detection. The test positivity threshold needs to be equivalent to the WHO protective threshold of 0.1 IU/mL in serum. Proof of concept studies at the University of Birmingham estimate that the protective cut-off in serum is equivalent to ~ 0.0024 IU/mL in saliva. Minimal time to perform, able to be completed with a small number of simple steps and return a result within 15 minutes. Reader-free and return a qualitative (positive or negative) result. The method of saliva sample collection to accompany the test needs to be suitable for use in young children and infants. The test should be able to be completed by a non-specialist and in a community or field setting. The test should have no linked required cold chain, able to withstand hot/humid temperatures on land and able to withstand conditions associated with transport by both aeroplane and drone. The test needs to be stable, with a long-term stability time equivalent to existing commercial lateral flow tests. The design of the test needs to be as low-cost as possible. This is to enable its use in low-middle income countries or low resource settings. The test design also needs to strongly reflect environmental considerations. Specifically, an unhoused test strip is desirable. The sample collection and application, and any other test components, should be designed and utilised with the objective of using as little plastic as possible and minimal packaging. The project will require developing the test to meet these desired specifications, evaluating the test performance (for example performance around the cut-off, reproducibility, stability and any other relevant domains, as informed by international guidelines on test evaluation e.g. CLSI) and supplying UoB with devices. Small batches of devices (~ 200) will need to be supplied to UoB at various points in the development to assess clinical accuracy. On completion of the project, the CRO will need to be able to supply UoB with up to 1000 devices suitable for use at the point of care as part of an in-field evaluation study. The development needs to be carried out within appropriate Quality Management Systems and in accordance with regulatory requirements for medical devices. The supplier should be certified to ISO 13485 and able to develop test to be compliant with IVDR 2017/746 requirements. The project should include the compiling and supply of relevant documentation and files to support future submission for regulatory approval. Post-project, the CRO should be able to support any future manufacture, scale-up and distribution of the test.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-044da5
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/010057-2024
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

38 - Laboratory, optical and precision equipments (excl. glasses)


CPV Codes

38000000 - Laboratory, optical and precision equipments (excl. glasses)

Notice Value(s)

Tender Value
£230,000 £100K-£500K
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
27 Mar 20241 years ago
Submission Deadline
26 Apr 2024Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Active
Awards Status
Not Specified
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
THE UNIVERSITY OF BIRMINGHAM
Contact Name
Kseniya Samsonik
Contact Email
k.samsonik@bham.ac.uk
Contact Phone
Not specified

Buyer Location

Locality
BIRMINGHAM
Postcode
B15 2TT
Post Town
Birmingham
Country
England

Major Region (ITL 1)
TLG West Midlands (England)
Basic Region (ITL 2)
TLG3 West Midlands
Small Region (ITL 3)
TLG31 Birmingham
Delivery Location
TLG3 West Midlands

Local Authority
Birmingham
Electoral Ward
Edgbaston
Westminster Constituency
Birmingham Edgbaston

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-044da5-2024-03-27T13:44:19Z",
    "date": "2024-03-27T13:44:19Z",
    "ocid": "ocds-h6vhtk-044da5",
    "initiationType": "tender",
    "tender": {
        "id": "SC12346/24",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "TENDER FOR THE DEVELOPMENT AND SUPPLY OF A SALIVA-BASED LATERAL FLOW IMMUNOASSAY",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "38000000",
            "description": "Laboratory, optical and precision equipments (excl. glasses)"
        },
        "mainProcurementCategory": "goods",
        "description": "The University of Birmingham invites tenders for the development and supply of lateral flow immunoassay. The lateral flow is intended to be used to detect antibodies in human saliva samples. Specifically, the lateral flow assay needs to be able to detect IgG-class anti-tetanus antibodies. The lateral flow immunoassay will need to be developed to meet the following key target specifications: High sensitivity detection that can differentiate protective antibody status. To enable its use with saliva specimens, the test will need to have a low limit of detection. The test positivity threshold needs to be equivalent to the WHO protective threshold of 0.1 IU/mL in serum. Proof of concept studies at the University of Birmingham estimate that the protective cut-off in serum is equivalent to ~ 0.0024 IU/mL in saliva. Minimal time to perform, able to be completed with a small number of simple steps and return a result within 15 minutes. Reader-free and return a qualitative (positive or negative) result. The method of saliva sample collection to accompany the test needs to be suitable for use in young children and infants. The test should be able to be completed by a non-specialist and in a community or field setting. The test should have no linked required cold chain, able to withstand hot/humid temperatures on land and able to withstand conditions associated with transport by both aeroplane and drone. The test needs to be stable, with a long-term stability time equivalent to existing commercial lateral flow tests. The design of the test needs to be as low-cost as possible. This is to enable its use in low-middle income countries or low resource settings. The test design also needs to strongly reflect environmental considerations. Specifically, an unhoused test strip is desirable. The sample collection and application, and any other test components, should be designed and utilised with the objective of using as little plastic as possible and minimal packaging. The project will require developing the test to meet these desired specifications, evaluating the test performance (for example performance around the cut-off, reproducibility, stability and any other relevant domains, as informed by international guidelines on test evaluation e.g. CLSI) and supplying UoB with devices. Small batches of devices (~ 200) will need to be supplied to UoB at various points in the development to assess clinical accuracy. On completion of the project, the CRO will need to be able to supply UoB with up to 1000 devices suitable for use at the point of care as part of an in-field evaluation study. The development needs to be carried out within appropriate Quality Management Systems and in accordance with regulatory requirements for medical devices. The supplier should be certified to ISO 13485 and able to develop test to be compliant with IVDR 2017/746 requirements. The project should include the compiling and supply of relevant documentation and files to support future submission for regulatory approval. Post-project, the CRO should be able to support any future manufacture, scale-up and distribution of the test.",
        "value": {
            "amount": 230000,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "1",
                "description": "The University of Birmingham invites tenders for the development and supply of lateral flow immunoassay. The lateral flow is intended to be used to detect antibodies in human saliva samples. Specifically, the lateral flow assay needs to be able to detect IgG-class anti-tetanus antibodies. The lateral flow immunoassay will need to be developed to meet the following key target specifications: High sensitivity detection that can differentiate protective antibody status. To enable its use with saliva specimens, the test will need to have a low limit of detection. The test positivity threshold needs to be equivalent to the WHO protective threshold of 0.1 IU/mL in serum. Proof of concept studies at the University of Birmingham estimate that the protective cut-off in serum is equivalent to ~ 0.0024 IU/mL in saliva. Minimal time to perform, able to be completed with a small number of simple steps and return a result within 15 minutes. Reader-free and return a qualitative (positive or negative) result. The method of saliva sample collection to accompany the test needs to be suitable for use in young children and infants. The test should be able to be completed by a non-specialist and in a community or field setting. The test should have no linked required cold chain, able to withstand hot/humid temperatures on land and able to withstand conditions associated with transport by both aeroplane and drone. The test needs to be stable, with a long-term stability time equivalent to existing commercial lateral flow tests. The design of the test needs to be as low-cost as possible. This is to enable its use in low-middle income countries or low resource settings. The test design also needs to strongly reflect environmental considerations. Specifically, an unhoused test strip is desirable. The sample collection and application, and any other test components, should be designed and utilised with the objective of using as little plastic as possible and minimal packaging. The project will require developing the test to meet these desired specifications, evaluating the test performance (for example performance around the cut-off, reproducibility, stability and any other relevant domains, as informed by international guidelines on test evaluation e.g. CLSI) and supplying UoB with devices. Small batches of devices (~ 200) will need to be supplied to UoB at various points in the development to assess clinical accuracy. On completion of the project, the CRO will need to be able to supply UoB with up to 1000 devices suitable for use at the point of care as part of an in-field evaluation study. The development needs to be carried out within appropriate Quality Management Systems and in accordance with regulatory requirements for medical devices. The supplier should be certified to ISO 13485 and able to develop test to be compliant with IVDR 2017/746 requirements. The project should include the compiling and supply of relevant documentation and files to support future submission for regulatory approval. Post-project, the CRO should be able to support any future manufacture, scale-up and distribution of the test.",
                "contractPeriod": {
                    "durationInDays": 360
                },
                "hasRenewal": false,
                "submissionTerms": {
                    "variantPolicy": "notAllowed"
                },
                "hasOptions": false,
                "status": "active"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UKG3"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "submissionMethod": [
            "electronicSubmission"
        ],
        "submissionMethodDetails": "https://in-tendhost.co.uk/universityofbirmingham/aspx/Home",
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "coveredBy": [
            "GPA"
        ],
        "tenderPeriod": {
            "endDate": "2024-04-26T12:00:00+01:00"
        },
        "submissionTerms": {
            "languages": [
                "en"
            ]
        },
        "awardPeriod": {
            "startDate": "2024-04-26T12:01:00+01:00"
        },
        "bidOpening": {
            "date": "2024-04-26T12:01:00+01:00"
        },
        "hasRecurrence": false
    },
    "parties": [
        {
            "id": "GB-COH-RC000645",
            "name": "THE UNIVERSITY OF BIRMINGHAM",
            "identifier": {
                "legalName": "THE UNIVERSITY OF BIRMINGHAM",
                "id": "RC000645",
                "scheme": "GB-COH"
            },
            "address": {
                "streetAddress": "Edgbaston",
                "locality": "BIRMINGHAM",
                "region": "UKG31",
                "postalCode": "B152TT",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Kseniya Samsonik",
                "email": "k.samsonik@bham.ac.uk",
                "url": "https://in-tendhost.co.uk/universityofbirmingham/aspx/Home"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.birmingham.ac.uk/",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "09",
                        "description": "Education"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-7158",
            "name": "University of Birmingham",
            "identifier": {
                "legalName": "University of Birmingham"
            },
            "address": {
                "locality": "Edgbaston",
                "postalCode": "B15 2TT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ]
        }
    ],
    "buyer": {
        "id": "GB-COH-RC000645",
        "name": "THE UNIVERSITY OF BIRMINGHAM"
    },
    "language": "en"
}